KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Top Page
KYORIN Pharmaceutical Co.,Ltd.
(4569)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥1,848.00
▲(20.23% Upside)
Action:DowngradedDate:09/20/25
KYORIN Pharmaceutical's strong financial performance and attractive valuation are offset by bearish technical indicators. The company's robust revenue growth and profitability are promising, but liquidity concerns and negative cash flow need addressing. The stock's low P/E ratio and high dividend yield suggest it is undervalued, offering potential for long-term investors despite current market momentum challenges.
Positive Factors
Consistent Revenue Growth
Sustained top-line expansion (roughly 8–10% YoY) indicates durable demand for KYORIN’s prescription portfolio in Japan. Persistent revenue growth supports continued R&D funding and commercialization scale, improving long-term competitiveness and reducing reliance on one-time gains.
Negative Factors
Weak Cash Conversion
Earnings are not translating efficiently into cash, with low OCF-to-net-income and persistent negative free cash flow. Over months to years this can constrain internal funding for trials, capex, dividends or create reliance on external financing, reducing strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained top-line expansion (roughly 8–10% YoY) indicates durable demand for KYORIN’s prescription portfolio in Japan. Persistent revenue growth supports continued R&D funding and commercialization scale, improving long-term competitiveness and reducing reliance on one-time gains.
Read all positive factors
KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥88.86B
Dividend Yield3.36%
Average Volume (3M)127.03K
Price to Earnings (P/E)8.4
Beta (1Y)0.56
Revenue Growth11.65%
EPS Growth93.46%
CountryJP
Employees2,042
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)45.70
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)0.66
P/FCF Ratio-39.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)81.05
Revenue Forecast (FY)¥126.47B
KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model
Company Description
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent;...
How the Company Makes Money
KYORIN Pharmaceutical primarily makes money by selling prescription pharmaceutical products. Its main revenue stream is domestic (Japan) sales of its branded medicines to medical institutions and through wholesalers, generating product sales reven...
KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 131.90B | 130.09B | 119.53B | 113.27B | 105.53B | 102.90B |
| Gross Profit | 60.43B | 59.51B | 51.62B | 50.16B | 49.44B | 51.62B |
| EBITDA | 18.34B | 17.15B | 10.52B | 8.96B | 8.72B | 9.34B |
| Net Income | 10.30B | 9.09B | 5.47B | 4.72B | 3.93B | 6.13B |
Balance Sheet | ||||||
| Total Assets | 190.57B | 193.62B | 177.63B | 176.04B | 171.92B | 167.13B |
| Cash, Cash Equivalents and Short-Term Investments | 16.62B | 16.51B | 13.98B | 19.39B | 27.49B | 30.84B |
| Total Debt | 26.48B | 28.44B | 20.95B | 21.28B | 21.62B | 21.88B |
| Total Liabilities | 54.41B | 57.33B | 46.89B | 50.58B | 47.41B | 42.46B |
| Stockholders Equity | 136.15B | 136.28B | 130.74B | 125.46B | 124.51B | 124.66B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.19B | -4.23B | -4.32B | 3.90B | 1.12B |
| Operating Cash Flow | 0.00 | 3.51B | 1.55B | 2.01B | 6.35B | 5.19B |
| Investing Cash Flow | 0.00 | -6.32B | -3.19B | -6.28B | -2.56B | -4.26B |
| Financing Cash Flow | 0.00 | 3.95B | -3.35B | -3.36B | -4.11B | -4.92B |
KYORIN Pharmaceutical Co.,Ltd. Technical Analysis
Positive
1537.00
Price Trends
1630.51
Positive
1556.47
Positive
1504.59
Positive
Market Momentum
22.24
Negative
60.47
Neutral
82.43
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Positive. The current price of 1537 is below the 20-day moving average (MA) of 1638.74, below the 50-day MA of 1630.51, and above the 200-day MA of 1504.59, indicating a bullish trend. The MACD of 22.24 indicates Negative momentum. The RSI at 60.47 is Neutral, neither overbought nor oversold. The STOCH value of 82.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4569.
KYORIN Pharmaceutical Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥152.00B | 93.62 | -2.58% | 4.16% | -5.99% | -96.04% | |
79 Outperform | ¥196.06B | 14.92 | 6.70% | 2.48% | 13.11% | 41.57% | |
77 Outperform | ¥356.57B | 9.44 | ― | 2.12% | 4.07% | 22.59% | |
73 Outperform | ¥120.29B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥88.86B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
67 Neutral | ¥211.62B | 5.05 | 12.02% | 2.14% | 9.32% | 30.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,695.00
316.72
22.98%
JP:4521
Kaken Pharmaceutical Co
4,190.00
17.95
0.43%
JP:4547
Kissei Pharmaceutical Co
4,770.00
1,220.69
34.39%
JP:4553
Towa Pharmaceutical Co
4,305.00
1,871.54
76.91%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,500.00
539.18
18.21%
JP:4516
Nippon Shinyaku Co., Ltd.
5,243.00
1,819.00
53.13%
KYORIN Pharmaceutical Co.,Ltd. Corporate Events
KYORIN Licenses BIODOL’s Novel Neuropathic Pain Drug for Key Asian Markets
Mar 31, 2026
KYORIN Pharmaceutical has exercised an option with France’s BIODOL Therapeutics to secure exclusive rights to develop, manufacture, and commercialize BDT272, a novel neuropathic pain treatment candidate, in Japan, South Korea, and Taiwan. Th...
KYORIN Secures Exclusive Japan Rights to Promote and Distribute J&J’s SIRTURO
Mar 25, 2026
KYORIN Pharmaceutical has signed an exclusive distribution and promotion agreement in Japan with Johnson Johnson’s Janssen unit for SIRTURO, an oral diarylquinoline antimycobacterial drug already marketed domestically as part of combination...
Kyorin Pharma Overhauls Governance With New Mandate-Based Officer System
Feb 26, 2026
Kyorin Pharmaceutical will introduce a mandate-based corporate officer system from April 1, 2026, alongside its existing employment-based framework. The move is designed to strengthen corporate governance by further separating decision-making and ...
KYORIN Wins Approval for Faster, More Sensitive GeneSoC FluA/B Influenza Test Kit
Feb 4, 2026
KYORIN Pharmaceutical has received regulatory approval from Japan’s Ministry of Health, Labour and Welfare for its new GeneSoC FluA/B Detection Kit, an in vitro diagnostic designed to rapidly detect and differentiate influenza A and B viruse...
KYORIN Pharma Releases Nine-Month Consolidated Results and Outlook
Feb 4, 2026
KYORIN Pharmaceutical Co., Ltd. released supplementary information on its consolidated financial results for the nine months ended December 31, 2025, covering business performance highlights, detailed financial outcomes, forecasts, main product sa...
KYORIN Pharmaceutical Lifts Nine-Month Profit but Keeps Lower Full-Year Outlook
Feb 4, 2026
KYORIN Pharmaceutical reported consolidated net sales of ¥92.5 billion for the nine months ended December 31, 2025, up 3.6% year on year, with operating profit surging 47.9% to ¥4.6 billion and profit attributable to owners of parent jum...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.